1World Health Organization. Cardiovascular diseases, fact sheet 2017.

2(2018) National Heart, Lung, and Blood Institute. Coronary heart disease.

3Lloyd-Jones DM, Hong Y, Labarthe D, et al. (2010) Defining and setting national goals for cardiovascular health promotion and disease reduction: The American heart association's strategic impact goal through 2020 and beyond. Circulation 121:586-613.

4Benjamin EJ, Virani SS, Callaway CW, et al. (2018) Heart disease and stroke statistics-2018 update: A report from the American heart association. Circulation.

5Hunter J. A (2007) treatise on the blood, inflammation, and gun-shot wounds. 1794 Clin Orthop Relat Res. 458:27-34.

6Folkman J (1971) Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186.

7Murray JD, Carlson GW, McLaughlin K, et al. (1997) Tumor angiogenesis as a prognostic factor in laryngeal cancer. Am J Surg 174:523-526.

8Senger DR, Galli SJ, Dvorak AM, Perruzzi CA (1983) Tumor cells secrete a vascular permeability factor that promotes the accumulation of ascites fluid. Science 219:983-985.

9Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. BiochemBiophys Res Commun 161:851-858.

10Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400.

11Taimeh Z, Loughran J, Birks EJ, Bolli R (2013) Vascular endothelial growth factor in heart failure. Nat Rev Cardiol 10:519-530.

12Ucuzian AA, Gassman AA, East AT, Greisler HP (2010) Molecular mediators of angiogenesis. J Burn Care Res. 31:158-175.

13Fearnley GW, Smith GA, Harrison MA, et al. (2013) Vascular endothelial growth factor-A regulation of blood vessel sprouting in health and disease. OA Biochemistry 1.

14Fearnley GW, Smith GA, Abdul-Zani I, et al. (2016) VEGF-A isoforms program differential VEGFR2 signal transduction, trafficking, and proteolysis. Biol Open 5:571-583.

15Smith GA, Fearnley GW, Harrison MA, Tomlinson DC, (2015) Vascular endothelial growth factors: Multitasking functionality in metabolism, health, and disease. J Inherit Metab Dis. 38:753-763.

16Harper SJ, Bates DO (2008) VEGF-A splicing: The key to anti-angiogenic therapeutics? Nat Rev Cancer. 8:880-887.

17Karki S, Ngo DTM, Farb MG, et al. (2017) WNT5A regulates adipose tissue angiogenesis via anti angiogenic VEGF-A165b in obese humans. Am J Physiol Heart Circ Physiol. 313: H200-H206.

18Kikuchi R, Nakamura K, MacLauchlan S, et al. (2014) An anti angiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease. Nat Med 20:1464-1471.

19Eswarappa SM, Potdar AA, Koch WJ, et al. (2014) Programmed translational read-through generates anti angiogenic VEGF-ax. Cell 157:1605-1618.

20Atluri P, Woo YJ (2008) Pro-angiogenic cytokines as cardiovascular therapeutics: Assessing the potential. Bio Drugs. 22:209-222.

21Eppler SM, Combs DL, Henry TD, et al. (2002) A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther. 72:20-32.

22Sato K, Wu T, Laham RJ, et al. (2001) Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. J Am Coll Cardiol 37:616-623.

23Henry TD, Annex BH, McKendall GR, et al. (2003) The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107:1359-1365.

24Gyongyosi M, Khorsand A, Zamani S, et al. (2005) NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: Sub analysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation 112:I157-1165.

25Stewart DJ, Kutryk MJ, Fitchett D, et al. (2009) VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: Results of the NORTHERN trial. MolTher 17:1109-1115.

26Hedman M, Hartikainen J, Syvanne M, et al. (2003) Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of post angioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: Phase II results of the Kuopio angiogenesis trial (KAT). Circulation. 107:2677-2683. .

27Kastrup J, Jorgensen E, Fuchs S, et al. (2011) A randomized, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: The NOVA trial. EuroIntervention 6:813-818.

28Cleland JL, Duenas ET, Park A, et al. (2001) Development of poly-(D, L-lactide-coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. J Control Release. 72:13-24.

29Simon-Yarza T, Formiga FR, Tamayo E, et al.(2012) Vascular endothelial growth factor-delivery systems for cardiac repair: An overview. Theranostics 2:541-552.

30Prestwich GD, Erickson IE, Zarembinski TI, et al. (2012) The translational imperative: Making cell therapy simple and effective. Acta Biomater 8:4200-4207.

31Grdisa M (2011) The delivery of biologically active (therapeutic) peptides and proteins into cells. Curr Med Chem 18:1373-1379.

32Bender E (2016) Cell-based therapy: Cells on trial. Nature 540:106-108.

33Buzhor E, Leshansky L, Blumenthal J, et al. (2014) Cell-based therapy approaches The hope for incurable diseases. Regen Med 9:649-672.

34Kalladka D, Sinden J, Pollock K, et al. (2016) Human neural stem cells in patients with chronic ischaemic stroke (PISCES): A phase 1, first-in-man study. Lancet 388:787-796.

35Schaun MI, Eibel B, Kristocheck M, et al. (2016) Cell therapy in ischemic heart disease: Interventions that modulate cardiac regeneration. Stem Cells Int.

36Liebson PR (2015) Stem-cell angiogenesis and regeneration of the heart: Review of a saga of 2 decades. Clin Cardiol. 38:309-316.

37Payne TR, Oshima H, Okada M, et al. (2007) A relationship between vascular endothelial growth factor, angiogenesis, and cardiac repair after muscle stem cell transplantation into ischemic hearts. J Am Coll Cardiol 50:1677-1684.

38Matsumoto R, Omura T, Yoshiyama M, et al. (2005) Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler Thromb Vasc Biol. 25:1168-1173.

39Borlongan CV (2016) Age of PISCES: Stem-cell clinical trials in stroke. Lancet 388:736-738.

40Hou L, Kim JJ, Woo YJ, Huang NF (2016) Stem cell-based therapies to promote angiogenesis in ischemic cardiovascular disease. Am J Physiol Heart Circ Physiol. 310:455-465.

41Mackie AR, Losordo DW (2011) CD 34-positive stem cells: In the treatment of heart and vascular disease in human beings. Tex Heart Inst J 38:474-485.

42Sukmawati D, Tanaka R (2015) Introduction to the next generation of endothelial progenitor cell therapy: A promise in vascular medicine. Am J Transl Res 7:411-421.

43Halvorsen YC, Wilkison WO, Gimble JM (2000) Adipose-derived stromal cells--their utility and potential in bone formation. Int J ObesRelat Metab Disord 24 Suppl 4: S41-44.

44Kapur SK, Dos-AnjosVilaboa S, Llull R, Katz AJ (2015)Adipose tissue and stem/progenitor cells: Discovery and development. Clin Plast Surg. 42:155-167.

45Brown SA, Levi B, Lequeux C, Wong VW, Mojallal A, (2010) Basic science review on adipose tissue for clinicians. Plast Reconstr Surg.126:1936-1946.

46De Francesco F, Ricci G, D'Andrea F,et al. (2015) Human adipose stem cells: From bench to bedside. Tissue Eng Part B Rev 21:572-584.

47Zuk PA, Zhu M, Mizuno H, et al. (2001) Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng 7:211-228.

48Zuk PA, Zhu M, Ashjian P, et al. (2002) Human adipose tissue is a source of multipotent stem cells. MolBiol Cell 13:4279-4295.

49Strem BM, Hicok KC, Zhu M, et al.(2005) Multipotential differentiation of adipose tissue-derived stem cells. Keio J Med 54:132-141.

50Lavoie JR, Rosu-Myles M (2013) Uncovering the secrets of mesenchymal stem cells. Biochimie 95:2212-2221.

51Brown JC, Shang H, Li Y, et al. (2017) Isolation of adipose-derived stromal vascular fraction cells using a novel point-of-care device: Cell characterization and review of the literature. Tissue Eng Part C Methods 23:125-135.

52Zuk PA, Zhu M, Ashjian P, et al. (2002) Human adipose tissue is a source of multipotent stem cells. MolBiol Cell 13:4279-4295.

53Kilroy GE, Foster SJ, Wu X, et al. (2007) Cytokine profile of human adipose-derived stem cells: Expression of angiogenic, hematopoietic, and pro-inflammatory factors. J Cell Physiol 212:702-709.

54Planat-Benard V, Menard C, Andre M, et al. (2004) Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ Res 94:223-229.

55Strem BM, Zhu M, Alfonso Z, et al. (2005) Expression of cardiomyocytic markers on adipose tissue-derived cells in a murine model of acute myocardial injury. Cytotherapy 7:282-291.

56Fraser JK, Schreiber R, Strem B, et al. (2006) Plasticity of human adipose stem cells toward endothelial cells and cardiomyocytes. Nat Clin Pract Cardiovasc Med 3Suppl 1: S33-37.

57Ankrum JA, Ong JF, Karp JM (2014) Mesenchymal stem cells: Immune evasive, not immune privileged. Nat Biotechnol 32:252-260.

58Zhao L, Johnson T, Liu D (2017) Therapeutic angiogenesis of adipose-derived stem cells for ischemic diseases. Stem Cell Res Ther 8:125.

59Sussman MA, Murry CE (2008) Bones of contention: Marrow-derived cells in myocardial regeneration. J Mol Cell Cardiol 44:950-953.

60Thakker R, Yang P (2014) Mesenchymal stem cell therapy for cardiac repair. Curr Treat Options Cardiovasc Med 16:323.

61Rehman J, Traktuev D, Li J, et al. (2004) Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 109:1292-1298.

62Kapur SK, Katz AJ (2013) Review of the adipose-derived stem cell secretome. Biochimie 95:2222-2228.

63Gnecchi M, He H, Noiseux N, et al. (2006) Evidence supporting the paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 20:661-669.

64Kinnaird T, Stabile E, Burnett MS, et al. (2004) Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 94:678-685.

65Crivellato E (2011) The role of angiogenic growth factors in organogenesis. Int J Dev Biol 55:365-375.

66Risau W (1998) Development and differentiation of endothelium. Kidney Int Suppl 67: S3-6.

67Ribatti D (2006) Genetic and epigenetic mechanisms in the early development of the vascular system. J Anat. 208:139-152.

68Slack J (2018) Organogenesis. In: The science of stem cells. 2018th ed. Hoboken, NJ: Wiley Blackwell 144-145.

69Cleaver O, Melton DA (2003) Endothelial signaling during development. Nat Med 9:661-668.

70Duan X, Murata Y, Liu Y, Nicolae C (2015) Vegfa regulates perichondrial vascularity and osteoblast differentiation in bone development. Development 142 :1984-1991.

71Street J, Lenehan B (2009) Vascular endothelial growth factor regulates osteoblast survival - evidence for an autocrine feedback mechanism. J Orthop Surg Res 4:19.

72Berendsen AD, Olsen BR (2014) How vascular endothelial growth factor-A (VEGF) regulates differentiation of mesenchymal stem cells. J Histochem Cytochem 62:103-108.

73Nakagami H, Maeda K, Morishita R, et al. (2005) Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler Thromb Vasc Biol. 25:2542-2547.

74Perin EC, Sanz-Ruiz R, Sanchez PL, et al. (2014) Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: The PRECISE trial. Am Heart J 168:88-95.

75Prasad K, Sharma A, Garg A, et al. (2014) Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: A multicentric, randomized trial. Stroke. 45:3618-3624.

76Nguyen PK, Rhee JW, Wu JC. (2016) Adult stem cell therapy and heart failure, 2000 to 2016: A systematic review. JAMA Cardiol 1:831-841.

77Houtgraaf JH, den Dekker WK, van Dalen BM, et al. (2012) First experience in humans using adipose tissue-derived regenerative cells in the treatment of patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 59:539-540.

78Kang T, Jones TM, Naddell C, et al. (2016) Adipose-derived stem cells induce angiogenesis via microvesicle transport of miRNA-31. Stem Cells Transl Med 5:440-450.

79Slack J (2018) What is a stem cell? In: The science of stem cells. 2018th ed. Hoboken, NJ: Wiley Blackwell :2.

80Kamprom W, Kheolamai P, U-Pratya Y, et al. (2016) Effects of mesenchymal stem cell-derived cytokines on the functional properties of endothelial progenitor cells. Eur J Cell Biol 95:153-163.

81Asahara T, Murohara T, Sullivan A, et al. (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967.

82Hur J, Yoon CH, Kim HS, et al. (2004) Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 24:288-293.

83Sanchez Alvarado A, Yamanaka S (2014) Rethinking differentiation: Stem cells, regeneration, and plasticity. Cell 157:110-119.

84Tavassoli M, Hardy CL (1990) Molecular basis of homing of intravenously transplanted stem cells to the marrow. Blood 76:1059-1070.

85Shi M, Li J, Liao L, et al. (2007) Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: Role in homing efficiency in NOD/SCID mice. Haematologica 92:897-904.

86Kronenwett R, Martin S, Haas R (2000) The role of cytokines and adhesion molecules for mobilization of peripheral blood stem cells. Stem Cells 18:320-330.